US Patent Issued to BeOne Medicines I on June 2 for "Bifunctional compounds for degradation of EGFR and related methods of use" (Chinese Inventors)

ALEXANDRIA, Va., June 2 -- United States Patent no. 12,643,903, issued on June 2, was assigned to BeOne Medicines I GmbH (Basel, Switzerland).

"Bifunctional compounds for degradation of EGFR and related methods of use" was invented by Bailin Lei (Beijing), Huaqing Liu (Beijing), Songzhe Han (Beijing) and Zhiwei Wang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof."

The patent was filed on Sept. 29, 2021, under Application No. 18/029...